Alera Pharma Launches with Neurology Focus and New Leadership

Alera Pharma, a fully owned US subsidiary of biopharmaceutical business Lobe Sciences, was established to create solutions for unmet medical needs. Psilocin Mucate, the company's new chemical entity, and its neurological assets will fall under the intellectual property rights of Alera. Alera's CEO will be Rick Goulburn, and its board of directors chairman will be Dr. Fred D. Sancilio.

Alera will operate as the neurology-focused operating firm under Lobe Sciences and will become the second operational subsidiary alongside Altemia, LLC. It is anticipated that Lobe Sciences Australia Pty Ltd., the Australian subsidiary, would merge with Alera. Ilan Hayman will become a member of Alera's senior management group. Dr. Sancilio stressed that Lobe Sciences' activities have been reduced to three organisations, with Lobe Sciences providing common services to the two operating subsidiaries.